This story is from the CurrentWire archive. Coverage details reflect the last time it was updated.
Teva Announces Positive Topline Results from Phase 2a Study in Celiac Disease for Its Anti-IL-15 Antibody, Further Validating Its Pipeline-in-a-Product Potential
Teva-discovered TEV ‘408, a novel anti-IL-15 monoclonal antibody, demonstrated statistically significant and clinically meaningful prevention of gluten-induced intestinal damage vs placebo following a single subcutaneous dose. TEV ‘408 was well-tolerated with no safety signals observed to date. Together with the vitiligo program, the celiac disease topline results further support TEV ‘408 as a potential pipeline-in-a-product […]
Financial Post
Published by CurrentWire · First coverage
Compiled by CurrentWire News Desk
Summary based on reporting from Financial Post.
In this story
Automated coverage analysis
Generated automatically from the coverage listed on this page. CurrentWire adds no editorial claims.
Coverage
1 publication is covering this story.
How CurrentWire compiled this story
Financial Post (financialpost.com), a Tier B publisher, filed this report on . CurrentWire published this page 25 minutes later, on .
Filed under General · International · News. Topics extracted from this report, with other live CurrentWire stories mentioning each: Positive Topline Results (none), Celiac Disease (none), Further Validating Its Pipeline-in-a-Product Potential (none).
CurrentWire is a news discovery platform. This page summarizes and links to original reporting; full articles, imagery and copyright remain with the publishers listed above.